Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells.

Martin ThelenDiandra KellerJonas LehmannKerstin WennholdHendrik WeitzEugen BauerBirgit GathofMonika BrüggemannMichaela KotrovaAlexander QuaasChristoph MallmannSeung-Hun ChonAxel M HillmerChristiane BrunsMichael von Bergwelt-BaildonMaria Alejandra Garcia-MarquezHans Anton Schlößer

Published in: Journal for immunotherapy of cancer (2023)

We identified the most relevant TAAs in EGA for monitoring of clinical trials and as therapeutic targets. Antigen-escape rather than missing immune response should be considered as mechanism underlying immunotherapy resistance of EGA.

Keyphrases

immune response
clinical trial
dendritic cells
toll like receptor
phase ii
nk cells
open label
phase iii
study protocol